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http:WHAT THIS PAPER ADDS
In this paper we propose a new anti-inﬂammatory role for simvastatin in human abdominal aortic aneurysm
(AAA) wall tissue. Simvastatin interferes with cyclophilin A (CyPA) formation and extracellular signal-regulated
protein kinases 1 and 2 (ERK1/2) activation. CyPA, a cyclosporine A-binding protein, inﬂuences AAA forma-
tion and the ERK1/2 signalling pathway in animal and in vitro studies and CyPA-deﬁcient mice are resistant to
aneurysm formation. Statins decrease CyPA in smooth muscle cells but their inﬂuence on CyPA in human AAA is
unknown. Therefore, investigating the statins in cardiovascular disease (CVD), such as AAA, may reveal new
therapeutic effects of those drugs.Background: Cyclophilin A (CyPA), a cyclosporine A-binding protein, inﬂuences abdominal aortic aneurysm (AAA)
formation and the ERK1/2 signalling pathway in animal and in vitro studies. Statins decrease CyPA in smooth
muscle cells although their inﬂuence on CyPA in human AAA is unknown.
Material and methods: The study was performed on AAA wall-tissue samples obtained from 30 simvastatin-
treated and 15 non-statin patients (2:1 case to control). The patients were matched by age, sex and AAA
diameter. We investigated the gene expression of CyPA, its receptor extracellular matrix metalloproteinase
inducer (EMMPRIN) by real-time RT-PCR. CyPA and EMMPRIN protein level and phosphorylated extracellular
signal-regulated kinases 1 and 2 (ERK1/2) were measured by Western blot.
Results: The AAA wall tissue from simvastatin-treated patients had signiﬁcantly lower CyPA gene expression and
protein levels (P ¼ 0.0018, P ¼ 0.0083, respectively). Furthermore, phosphorylation of ERK1 and ERK2 was
markedly suppressed in the simvastatin group (P ¼ 0.0002, P ¼ 0.0027, respectively). However, simvastatin did
not inﬂuence EMMPRIN gene and protein expression.
Conclusion: Simvastatin-treated patients with AAA exert lower CyPA messenger RNA (mRNA), as well as CyPA
intracellular protein levels and a decreased amount of phospho-ERK1/2. Thus, the interference with signalling
pathways leading to CyPA formation and ERK1/2 activation reveals a new anti-inﬂammatory role of statins in
AAA.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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health issue in the elderly, affecting approximately 10% of
individuals over 65.1 In Western countries AAA may cause
as much as 2% of all deaths.2 At our unit 1198 patients with
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//dx.doi.org/10.1016/j.ejvs.2013.02.015From the morphological point of view, the AAA is
considered as a dilatative form of atherosclerosis that is
critically connected with inﬂammation, oxidative stress and
degradation of the cellular matrix.3,4 Overproduction of
reactive oxygen species (ROS) is regarded as an important
driver that lies upstream of the inﬂammatory cascade.
Some mediators, which are induced in response to ROS,
were named secreted oxidative stress-induced factors
(SOXFs). Cyclophilin A (CyPA), a chaperone that binds
cyclosporine A, is highlighted as a major SOXF.5e7 Elevated
levels of CyPA have been reported in advanced athero-
sclerosis lesions3 and up-regulation of intracellular and
A. Piechota-Polanczyk et al. 683extracellular CyPA occurs during AAA formation in mice.8
Furthermore, excessive free radical generation during
ischaemia/reperfusion9 leads to increased CyPA production
by leucocytes and macrophages.10 Further, increased CyPA
protein levels are observed in polymorphonuclear neutro-
phils (PMNs) of AAA patients.11
CyPA wields its action when binding to the extracellular
matrix metalloproteinase inducer (EMMPRIN) receptor
localised on vascular smooth muscle cells (VSMCs).12
Recently Chen et al.13 demonstrated that EMMPRIN is
strongly expressed in human AAA lesions. The over-
expression of EMMPRIN leads to activation of the extra-
cellular signal-regulated kinases 1 and 2 (ERK1/2). The
cascade of EMMPRINeERKenuclear factor-kB (NF-kB) is
speculated to be the main signalling pathway for CyPA in
monocytes/macrophages.14
In our recent study we presented decreased activity of
the NF-kB signalling pathway and lowered level of ROS and
tumour necrosis factor (TNF)-a in AAA tissue from patients
treated with simvastatin.15 Simvastatin belongs to
hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors which, among others, inﬂuence aneurysm
formation.16,17 Suzuki et al.18 indicate that simvastatin
decreases ROS-mediated CyPA release from VSMC. Addi-
tionally, simvastatin inhibits angiotensin II-mediated stimu-
lation of ERK1/2 phosphorylation in VSMC.19 However, the
role of statins in intracellular CyPA level and their inﬂuence
on the ERK1/2 pathway in human AAA tissue remains
elusive.
Therefore, the aim of the study was to assess the inﬂu-
ence of simvastatin on cyclophilin A levels in AAA wall
tissue. Next, we wanted to verify if the ERK1/2 signalling
pathway is modulated by simvastatin in AAA wall tissue.
MATERIAL AND METHODS
Patients
The study was performed on 45 patients undergoing open
AAA repair between September 2009 and December 2011 at
our institution according to our previous study.15 Brieﬂy,
exclusion criteria were the intake of statins other than sim-
vastatin, non-steroidal anti-inﬂammatory drugs except
aspirin in the medication list, chronic diseases such as liver
disease, inﬂammatory disease, malignant disease, recrea-
tional drugs’ intake and alcohol abuse. Afterwritten informed
consent, patient data were prospectively collected and
aneurysm wall tissue was harvested during aneurysm repair
for retrospective analysis. Patients were matched in a 2
(simvastatin) to 1 (non-statin) ratio, respectively, by age,
gender and AAA diameter. Fifteen patients without statin
medication (12 men, 3 women) were incorporated into the
control group and 30 patients who had simvastatin (24 men,
6 women) in their medical history (20e40 mg daily dosage)
for a minimum of 6 months were included in the study as the
simvastatin group. The AAA diameter was measured with
preoperative computed tomography angiography (CTA).
Coronary artery disease (CAD) was deﬁned by a history of
angina pectoris or myocardial infarction. Cerebrovasculardisease (CVAD) was deﬁned by a history of transient
ischaemic attack, stroke, carotid artery stenting or surgery,
respectively. Cardiac insufﬁciency was deﬁned by a global
ejection fraction of <50% in echocardiography; all patients
were without cardiac symptoms at the time of the surgery.
Peripheral artery disease was deﬁned by symptomatic
claudication and a corresponding ﬁnding in the CTA at the
level of the iliac and/or femoro-popliteal vessels.
Hypertension was deﬁned by the intake of antihyper-
tensive and/or a repeatedly elevated blood pressure
exceeding 140 over 90 mmHg. Type 2 diabetes was deﬁned
by the intake of antidiabetics or requirement of insulin.
Dyslipidaemia was deﬁned as recommended in the Euro-
pean Society of Cardiology/European Atherosclerosis
Society (ESC/EAS) guidelines for the management of dysli-
pidaemia.20 Smoking (y/n) pertains to nicotine consumption
within the last 3 years.
The study was approved by the local research Ethics
Committee (EC 294/2009).
Tissue harvesting
After aortic cross-clamping and longitudinal incision of the
aneurysm, the thrombus (present in 39 of 45 patients) was
removed and about 3 cm2 of the aneurysm sac was excised
at the site of its maximum diameter. Aneurysm samples
were immediately frozen in liquid nitrogen and stored
at 80 C. For subsequent analysis aneurysm tissue was
processed on ice. The aneurysm wall was divided into 50-
mg pieces and rinsed with ice-cold saline to eliminate the
liquid components, such as blood and residual thrombi.
Western blot analyses of CyPA, EMMPRIN and ERK1/2
Equal protein amounts of tissue extracts were separated by
sodium dodecyl sulphate-polyacryalamide gel electropho-
resis (SDS-PAGE), and CyPA, EMMPRIN, p42, phospho-42,
p44 and phospho-44 were assessed by Western blotting
using the respective rabbit anti-human monoclonal anti-
bodies followed by horseradish peroxidase (HRP)-conju-
gated donkey secondary antibodies (Abcam, Cambridge, UK
and Cell Signalling, Danvers, MA, USA, respectively). Signal
intensity was quantiﬁed using an Imagine Master VDS (Bio-
Rad Laboratories Inc., Hercules, CA, USA) and normalised to
b-tubulin. Assays were performed twice with tissue samples
from different donors.
Real-time polymerase chain reaction for CyPA and
EMMPRIN
Frozen tissue was homogenised using a ball mill (Retsch,
Haan, Germany), and mRNA was isolated using the High Pure
RNA Tissue Kit (Roche, Basel, Switzerland). Reverse tran-
scription was performed using Transcriptor First Strand cDNA
Synthesis Kit (Roche). Real-time polymerase chain reaction
(PCR)was performed using the LightCycler TaqManMaster
(Roche) according to themanufacturer’s instructions. Primers
were designed using the Roche Universal ProbeLibrary Assay
Design Centre: glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (forward primer: 50-AGCCACATCGCTCAGACAC-30,
684 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 6 June/2013reverse primer: 50-GCCCAATACGACCAAATCC-30), CypA
(forward primer 50-GTCAACCCCACCGTGTTCTTC-30, reverse
primer: 50-TTTCTGCTGTCTTTGGGACCTTG-30) and EMMPRIN
(forward primer. 50-GGGAGAGTACTCCTGCGTCTT-30, reverse
primer: 50-ACTTCACAGCCTTCACTCTGG-30). The ampliﬁcation
conditions consisted of an initial incubation at 95 C for
10 min, followed by 45 cycles of 95 C for 10 s, 63 C for 20 s
and 72 C for 6 s and a ﬁnal cooling to 40 C. Data were
analysed using LightCycler Software Version 3.5 (Roche).
Statistical analysis
Continuous demographic and biochemical data are pre-
sented as median, minimum and maximum, and demo-
graphic categorical data are described with absolute
frequencies and percentages. Data are 2:1 matched in the
simvastatin and non-statin groups. A generalised linear
model (binomial, logit) with an exchangeable correlation
matrix was used to analyse matched binary outcome data.
A linear mixed model with a compound symmetry vari-
anceecovariance matrix was used to analyse matched
continuous outcome data. In the case of skew residuals
a logarithmic transformation usually led to normally
distributed errors.
All P-values are two-sided and P  0.05 was considered
signiﬁcant. Statistical analyses were performed by the
software package SAS (Version 9.3; SAS Institute Inc., Cary,
NC, USA) and the software package Statistical Package for
the Social Sciences (SPSS) (SPSS 17.0, Chicago, IL, USA) was
used for graphics.
RESULTS
Demographic data
In Table 1, the characteristics for non-statin and
simvastatin-treated patients are shown. The two groupsTable 1. Patient demographics.
Non-statin patients (
Age (years), median (range) 68 (50e73)
Sex (male) 12 (80%)
AAA diameter (mm) 57 (48e102)
Body mass index, mean (range) 27.55 (21.95e37.55)
Coronary artery disease 3 (20%)
Cerebrovascular artery disease 10 (67%)
Peripheral artery disease 4 (27%)
Cardiac insufﬁciency 1 (7%)
Hypertension 15 (100%)
Type 2 diabetes 4 (27%)
Smoking 12 (80%)
Cholesterol [mg/dl], median (range)a 240 (143e323)
LDL [mg/dl], median (range)a 164.4 (79.2e218)
HDL [mg/dl], median (range)a 45.0 (36e68)
CRP [mg/dl], median (range)a 0.43 (0.03e7.6)
Fibrinogen [mg/dl], median (range)a 407 (280e594)
Leucocytes [mln/ml], median (range)a 8.15 (5.5e12)
Creatinine [mg/dl], median (range)a 1.05 (0.75e1.44)
Data are presented as frequencies or median (minimumemaximum
generalised linear models, while metric values were analysed using lin
a The measurements were made in serum samples.were comparable in age, aneurysm diameter, co-morbidities
and risk factors. The median aneurysm diameter was 57 mm
(48e102 mm) for the non-statin and 55 mm (48e120 mm)
for the simvastatin patients. The simvastatin group had
markedly lower body mass index (P ¼ 0.025) and better
lipid proﬁle with signiﬁcantly decreased total cholesterol
and low density lipoprotein (LDL) cholesterol (P ¼ 0.002
and P ¼ 0.003, respectively). We found no differences in
C-reactive protein (CRP), ﬁbrinogen, creatinine and leuco-
cyte levels among the two groups (all P  0.05).Simvastatin decreases CyPA gene expression and protein
level in human AAA wall explants
The tissue gene expression of CyPA from AAA patients
treated with simvastatin was signiﬁcantly lower than in the
non-statin group (P ¼ 0.0018, Fig. 1(A)). Similarly, the
intracellular CyPA protein level was markedly decreased in
the simvastatin group when compared to the non-statin
group (P ¼ 0.0083, Fig. 1(B) and (C)). However, there was
no difference in the tissue gene expression and the protein
level of EMMPRIN in the two examined groups (P ¼ 0.6495
and P ¼ 0.408, respectively; Fig. 2(A) and (B)). Fig. 2(C)
shows a representative Western blot including three sim-
vastatin and two non-statin patients.Simvastatin reduces pERK1/2 in human AAA wall explants
In Fig. 3(A) the densitometric analysis comparing 30 sim-
vastatin and 15 non-statin patients is shown (2:1 case to
control). The amounts of phospho-p42/p42 (pERK1) and
phospho-p44/p-44 (pERK2) were signiﬁcantly lower in AAA
tissues from simvastatin patients when compared to the
non-statin group (P ¼ 0.0002 and P ¼ 0.0027, respectively)
(Fig. 3(A) and (B)). Fig. 3(C) shows a representative Westernn ¼ 15) Simvastatin patients (n ¼ 30) P
67 (55e80) 0.186
24 (80%) 1.000
55 (48e120) 0.439
25.89 (21.56e31.25) 0.025
9 (30%) 0.479
15 (50%) 0.161
9 (30%) 0.803
8 (23%) 0.083
28 (93%) 0.317
8 (27%) 1.000
22 (73%) 0.617
199 (110e264) 0.002
112.5 (47e218) 0.003
48.0 (29e75) 0.477
0.43 (0.06e3.0) 0.291
359 (240e549) 0.102
8.0 (5.09e13.0) 0.473
0.99 (0.76e4.0) 0.907
). Statistical signiﬁcance for binary variables was assessed using
ear mixed regression models.
Figure 1. Simvastatin treatment suppressed CyPA mRNA expres-
sion and CyPA protein level in human AAA wall tissue. (A) CyPA
mRNA expression. (B) Densitometrical quantiﬁcation of CyPA
protein level (mean values  SD). (C) Representative Western blot
(n ¼ 2 and n ¼ 3 for AAA tissue wall from the non-statin and
simvastatin patients, respectively).
Figure 2. Simvastatin treatment had no inﬂuence on EMMPRIN
mRNA expression and protein level in human AAA wall tissue.
(A) EMMPRIN gene expression. (B) Densitometrical quantiﬁcation
of EMMPRIN protein level (mean values  SD). (C) Representative
Western blot (n ¼ 2 and n ¼ 3 for AAA tissue wall from the non-
statin and simvastatin patients, respectively).
A. Piechota-Polanczyk et al. 685blot including three simvastatin and two non-statin
patients.
DISCUSSION
In the present study we showed that AAA wall tissue from
patients treated with simvastatin has lower gene expression
and intracellular concentration of CyPA. Moreover,
simvastatin-treated subjects with AAA had lower activity of
the ERK1/2 signalling pathway compared to age-, sex- and
AAA diameter-matched non-statin patients. However, we
observed no difference in the gene expression and the
protein level of EMMPRIN between the simvastatin and
non-statin AAA wall tissue.
AAA development is a multifactorial process that
depends to a great extent on macrophage-derived matrix
metalloproteinase-9 (MMP-9) and VSMC-derived MMP-2.21
Statins were shown to interfere with AAA expansion;
however their role remains controversial. Recently, Takagiet al.17 indicated that statin therapy might be effective in
prevention of the growth of small AAA, while Karrowni
et al.22 showed no correlation. Further, controversies have
arisen around statin inﬂuence on VSMC proliferation which
number is decreased in the media of human AAA tissue.23
Here some studies highlight the anti-proliferative role of
statins in the neointima while others described their
proliferative action under hyperglycaemia.24,25 Yet it is not
clear whether the induction of apoptosis in VSMC by statins
is beneﬁcial or detrimental. Nevertheless, it is apparent that
a short course of cyclosporine A, a CyPA-binding drug,
stabilises the diameter of formed AAA and increases VSMC
content in an animal model.26
It was previously demonstrated that AAA tissue had
a higher concentration of CyPA than the healthy aorta;3,27
increased CyPA levels were found in PMNs in AAA
patients.11 Therefore, drugs that inﬂuence CyPA concen-
tration may impact AAA formation. Statins whose
Figure 3. Simvastatin treatment inhibited p-ERK1 (A) and p-ERK2
(B) activation in human AAA wall samples. (C) Representative
Western blot (n ¼ 2 and n ¼ 3 for AAA tissue wall from the non-
statin and simvastatin patients, respectively). Data are present as
the ratio of phosphorylated form to total form (fold) over tubulin
and represents mean values  SD.
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sion and protein concentration of MMP-3, MMP-9 and TNF-
a and lead to an increase in antioxidant enzyme activity in
human AAA tissue may play an important role.15,28,29 Here
we present evidence that simvastatin treatment in patients
with AAA signiﬁcantly decreased CyPA in AAA wall on the
gene and protein levels. Our results are in line with the
study of Suzuki et al.,18 who suggested that simvastatin
inhibits vesicular secretion of CyPA in VSMC probably by
inhibiting isoprenylation of small guanosine triphosphatases
(GTPases).18 However, further studies are required to
investigate the mechanism of simvastatin-induced decrease
of CyPA in human AAA wall in detail.In cells CyPA exerts its action when it binds to the
EMMPRIN receptor,30 which is highly expressed in the
diseased aortic wall of AAA patients.13 So far there are
limited data about the inﬂuence of statins on EMMPRIN
tissue expression. Abe et al.31 indicated that ﬂuvastatin
inﬂuences EMMPRIN expression in macrophages probably
via its antioxidant properties. However, our study showed
no difference in the gene expression and protein level of
EMMPRIN in simvastatin and non-statin AAA wall tissue.
This may be explained by the occurrence of different cell
types such as VSMC, endothelial cells and immune cells in
aneurysm tissue.
AAA tissue is characterised by up-regulated activity of
different signalling transcription pathways including NF-kB
and activator protein-1 (AP-1).32 Lately Ghosh et al.33 re-
ported on increased activity of ERK1/2 in human AAA tissue
and reduced AAA formation after ERK1/2 inhibition in animal
models. Our results show a decreased amount of pERK1/2 in
AAA wall tissue in simvastatin-treated patients compared to
the non-statin group. ERK-mediated cell signals are essential
for cellular proliferation, differentiation and survival, and
improper activation of ERK1/2 is associated with immuno-
logical disorders.34 Both ERK isoforms are ubiquitously
expressed in almost all mammalian tissues, with ERK-2 levels
generally greater than ERK-1 levels. Recently, Bahmed et al.35
indicated that extracellular CyPA stimulates ERK1/2 phos-
phorylation in cancer cells and Jin et al.36 showed that CyPA
mediates phosphorylation of ERK1/2 and IkBa of NF-kB in
human endothelial cells. Therefore, decreased CyPA levels in
the simvastatin group observed in our studymay be causative
for the blunted activity of ERK1/2. This corresponds to the
report by Tristano et al.19 that the phosphorylation of ERK1/2
is inhibited by simvastatin in VSMC. Simvastatin also reduced
c-Raf and Ras expression, the components of mitogen-
activated protein kinase (MAPK) pathway, in VSMC during
high glucose conditions.37
Inhibition of phosphorylation of ERK1/2 by statins may be
potentially dangerous regarding preservation of VSMC. It
was indicated that simvastatin inhibits angiotensin
II-mediated stimulation of ERK1/2 but simvastatin with-
drawal escalates angiotensin II-mediated effect, therefore
leading to VSMC degradation.38 Nevertheless, targeting the
ERK1/2 pathway with drugs that inhibit either the expres-
sion CyPA or phosphorylation of ERK1/2 isoforms could be
a potential therapeutic approach to prevent AAA formation
as well as progression.CONCLUSION
Our study demonstrates that simvastatin treatment reduces
cyclophilin A gene expression and protein concentration in
human AAA wall tissue as compared to the non-statin
patients. Moreover, simvastatin inhibits phosphorylation
of the ERK1/2 signalling pathway. Thus, decreased CyPA
concentration in AAA tissue by simvastatin may inﬂuence
ERK1/2 inhibition suggesting a yet-unknown anti-inﬂam-
matory action of statins in human abdominal aortic
aneurysms.
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